Life Length, a Spain-based telomere diagnostics and analyses company, has successfully secured £1.97 million in funding through its equity crowdfunding campaign on Crowdcube. The round was launched last month and quickly surpassed its £650,000 funding target. It has also attracted nearly 700 investors.
Founded in 2010, Life Length is a biotech company created to bring to the market the most accurate telomere length analysis technology in the world. The company stated:
“Life Length was established to commercially exploit telomere length and telomerase activity measurement technologies, serving to the pharmaceutical industry, clinics and hospital, as well as research laboratories interested on bringing telomere and telomerase analysis into their studies and research projects.”
Life Length also noted that the ProsTAV is its sophisticated prostate cancer risk score test that we have developed with its proprietary technology thanks to a clinical study involving 1,200 prostate biopsied patients.
“Combined with the current screening methodology, this simple blood test can save hundreds of thousands of men each year from unnecessary biopsies, surgeries and needless complications. Our new test, less expensive and invasive than a biopsy, could save up to 50% of these unnecessary biopsies. It is a huge market with an estimated 6 million cases worldwide. In the UK, it is one of the most frequently diagnosed cancers (over 50,000 annually).”
Funds from the Crowdcube round will be used for the growth and expansion of the company’s technology. It is set to close mid-August.
Have a crowdfunding offering you'd like to share? Submit an offering for consideration using our Submit a Tip form and we may share it on our site!